Grifols Stock Forecast, Price & News

+0.47 (+2.59 %)
(As of 04/22/2021 12:00 AM ET)
Today's Range
Now: $18.60
50-Day Range
MA: $16.87
52-Week Range
Now: $18.60
Volume427,207 shs
Average Volume920,350 shs
Market Capitalization$12.79 billion
P/E Ratio16.61
Dividend Yield0.77%
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
Grifols logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:GRFS
Phone(493) 571-2200
Year Founded1909



Sales & Book Value

Annual Sales$5.71 billion
Cash Flow$1.61 per share
Book Value$11.15 per share


Net Income$700.16 million


Market Cap$12.79 billion
Next Earnings DateN/A


Grifols (NASDAQ:GRFS) Trading Up 3.6%
April 19, 2021 |
Form 6-K Grifols SA For: Apr 16 -
April 16, 2021 |
Grifols (NASDAQ:GRFS) Shares Gap Up to $17.11
April 8, 2021 |
Grifols (NASDAQ:GRFS) Stock Price Down 4%
April 1, 2021 |
See More Headlines


Overall MarketRank

1.25 out of 5 stars

Medical Sector

870th out of 2,024 stocks

Pharmaceutical Preparations Industry

409th out of 771 stocks

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -
+0.47 (+2.59 %)
(As of 04/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GRFS News and Ratings via Email

Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Grifols (NASDAQ:GRFS) Frequently Asked Questions

Is Grifols a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Grifols stock.
View analyst ratings for Grifols
or view top-rated stocks.

What stocks does MarketBeat like better than Grifols?

Wall Street analysts have given Grifols a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Grifols wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Grifols' earnings last quarter?

Grifols, S.A. (NASDAQ:GRFS) released its quarterly earnings data on Friday, February, 26th. The biotechnology company reported $0.29 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.38 by $0.09. The biotechnology company earned $1.56 billion during the quarter, compared to analyst estimates of $1.63 billion. Grifols had a net margin of 12.79% and a trailing twelve-month return on equity of 10.65%.
View Grifols' earnings history

How has Grifols' stock been impacted by Coronavirus?

Grifols' stock was trading at $20.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GRFS shares have decreased by 8.6% and is now trading at $18.60.
View which stocks have been most impacted by COVID-19

How often does Grifols pay dividends? What is the dividend yield for Grifols?

Grifols announced a semi-annual dividend on Thursday, October 22nd. Shareholders of record on Monday, November 2nd will be given a dividend of $0.1445 per share on Monday, November 9th. This represents a yield of 1.6%. The ex-dividend date of this dividend is Friday, October 30th.
View Grifols' dividend history

Is Grifols a good dividend stock?

Grifols pays an annual dividend of $0.14 per share and currently has a dividend yield of 0.77%. The dividend payout ratio of Grifols is 11.97%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Grifols will have a dividend payout ratio of 9.27% next year. This indicates that Grifols will be able to sustain or increase its dividend.
View Grifols' dividend history.

When did Grifols' stock split? How did Grifols' stock split work?

Grifols shares split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly minted shares were payable to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of Grifols stock prior to the split would have 200 shares after the split.

Who are Grifols' key executives?

Grifols' management team includes the following people:
  • Raimon Grifols Roura, Joint Chief Executive Officer & Executive Director
  • Victor Grifols Deu, Joint Chief Executive Officer & Executive Director
  • Alfredo Arroyo Guerra, Chief Financial Officer & Vice President
  • Xavier Sueiras Gil, Chief Information Technology Officer
  • Marilyn Rosa-Bray, Chief Medical Officer & Vice President-Quality

What is Raimon Grifols and Victor Grifols Deu's approval rating as Grifols' CEO?

205 employees have rated Grifols CEO Raimon Grifols and Victor Grifols Deu on Raimon Grifols and Victor Grifols Deu has an approval rating of 68% among Grifols' employees.

Who are some of Grifols' key competitors?

What other stocks do shareholders of Grifols own?

What is Grifols' stock symbol?

Grifols trades on the NASDAQ under the ticker symbol "GRFS."

Who are Grifols' major shareholders?

Grifols' stock is owned by many different retail and institutional investors. Top institutional shareholders include Cardinal Capital Management (0.01%), FDx Advisors Inc. (0.00%) and Reilly Financial Advisors LLC (0.00%).

Which major investors are selling Grifols stock?

GRFS stock was sold by a variety of institutional investors in the last quarter, including Reilly Financial Advisors LLC, and FDx Advisors Inc..

Which major investors are buying Grifols stock?

GRFS stock was bought by a variety of institutional investors in the last quarter, including Cardinal Capital Management.

How do I buy shares of Grifols?

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Grifols' stock price today?

One share of GRFS stock can currently be purchased for approximately $18.60.

How much money does Grifols make?

Grifols has a market capitalization of $12.79 billion and generates $5.71 billion in revenue each year. The biotechnology company earns $700.16 million in net income (profit) each year or $1.17 on an earnings per share basis.

How many employees does Grifols have?

Grifols employs 23,655 workers across the globe.

Does Grifols have any subsidiaries?

The following companies are subsidiares of Grifols: Aigües Minerals de Vilajuiga S.A., Araclon Biotech, Araclon Biotech S.L., Asociación I+D Progenika, Biomat S.A., Biomat USA Inc., Biotest Pharmaceutical Corporation, Biotest US Corporation, Chiquito Acquisition Corp., Diagnostic Grifols S.A., Goetech LLC (D/B/A Medkeeper), Gri-Cel S.A. , Grifols (H.K.) Limited, Grifols (Thailand) Ltd, Grifols Argentina S.A., Grifols Asia Pacific Pte Ltd, Grifols Australia Pty Ltd., Grifols Biologicals LLC., Grifols Brasil Lda., Grifols Canada Ltd., Grifols Chile S.A., Grifols Colombia Ltda, Grifols Deutschland GmbH, Grifols Diagnostics Equipment Taiwan Limited, Grifols Diagnostics Solutions Inc, Grifols Engineering S.A., Grifols France S.A.R.L., Grifols India Healthcare Private Ltd, Grifols Innovation and New Technologies Limited, Grifols International S.A., Grifols Italia S.p.A, Grifols Japan K.K., Grifols Malaysia Sdn Bhd, Grifols Movaco S.A., Grifols México S.A. de C.V., Grifols Nordic AB, Grifols Pharmaceutical Technology (Shanghai) Co. Ltd., Grifols Polska Sp.z.o.o., Grifols Portugal Productos Farmacéuticos e Hospitalares Lda., Grifols Shared Services North America Inc., Grifols Switzerland AG, Grifols Therapeutics LLC., Grifols UK Ltd., Grifols USA LLC., Grifols Viajes S.A., Grifols Worldwide Operations Limited, Grifols Worldwide Operations Spain S.A., Grifols Worldwide Operations USA Inc., Grifols s.r.o., Gripdan Invest S.L, Haema AG, Instituto Grifols S.A., Interstate Blood Bank Inc., Kiro Grifols S.L, Kiro Robotics, Laboratorios Grifols S.A., Logística Grifols S.A. de C.V., Medion Diagnostics GmbH, Medion Grifols Diagnostic AG, PBS Acquisition Corp., Progenika Biopharma, Progenika Biopharma S.A., Squadron Reinsurance Designated Activity Company, Talecris Biotherapeutics, Talecris Plasma Resources Inc., and VCN Bioscience S.L..

When was Grifols founded?

Grifols was founded in 1909.

What is Grifols' official website?

The official website for Grifols is

Where are Grifols' headquarters?

Grifols is headquartered at 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174.

How can I contact Grifols?

Grifols' mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at (493) 571-2200 or via email at [email protected]

This page was last updated on 4/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.